[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355103-105":59,"doc-detail-355103-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","design-synthesis-and-anti-breast-cancer-activity-evaluation-of-67-dihydro-5h-pyrrolo34-dpyrimidine-based-parp1atr-dual-inhibitors","Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based PARP1/ATR dual inhibitors","","PARP1 inhibitors are FDA-approved for BRCA1/2-mutated breast cancer but have limited efficacy in wild-type tumors and often encounter resistance. To address this, novel 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based compounds were designed by combining PARP1 inhibitor pharmacophores with the ATR inhibitor AZD6738 scaffold. Structural modifications altered PARP1 and ATR selectivity, producing dual inhibitors or selective PARP1 inhibitors. The lead compound 38a showed potent dual inhibition (IC50 \u003C 20 nM) and strong anti-tumor effects in MDA-MB-231 and MDA-MB-468 cells in vitro, including cell cycle arrest, apoptosis induction, reduced colony formation and migration, and suppressed DNA damage repair pathways, outperforming combined niraparib and AZD6738.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/design-synthesis-and-anti-breast-cancer-activity-evaluation-of-67-dihydro-5h-pyrrolo34-dpyrimidine-based-parp1atr-dual-inhibitors/355103/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/design-synthesis-and-anti-breast-cancer-activity-evaluation-of-67-dihydro-5h-pyrrolo34-dpyrimidine-based-parp1atr-dual-inhibitors/355103.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why were new PARP1/ATR dual inhibitors designed for breast cancer?","Question",{"text":113,"@type":114},"PARP1 inhibitors are effective mainly for BRCA1/2-mutated tumors, but resistance and limited efficacy occur in wild-type cancers. Co-targeting PARP1 and ATR is intended to overcome resistance linked to DNA damage repair and replication stress responses.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was the compound series constructed in the study?",{"text":118,"@type":114},"The researchers designed 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based compounds by integrating PARP1 inhibitor pharmacophores with the ATR inhibitor AZD6738 scaffold. Substituent modifications were used to tune PARP1 and ATR selectivity.",{"name":120,"@type":111,"acceptedAnswer":121},"What key in vitro effects did the lead compound 38a show?",{"text":122,"@type":114},"Compound 38a produced potent dual inhibition and strong anti-tumor activity in MDA-MB-231 and MDA-MB-468 cells. Mechanistically, it arrested the cell cycle, induced apoptosis, inhibited colony formation and migration, and suppressed DNA damage repair pathways.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355103,1790154976,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Journal of EnzymE InhIbItIon and mEdIcInal chEmIstry [https://doi.org/10.1080/14756366.2026.2627053](https://doi.org/10.1080/14756366.2026.2627053)  \nReseaRch aRticle    \nDesign, synthesis and anti-breast cancer activity evaluation of  \n6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based PARP1/ATR dual inhibitors  \nMeng-lan hea,b, Zong-hao Wanga,b, Xia Yaoa,b, lu-lu Yea, Bo-Qun Dua,b, chen-chen Wanga,c, Yong-hao chend, Xiao-Xian Wangd, hui luod, Yuan Gaoe and Xiang-Yang Yea,b   \naschool of Pharmacy, hangzhou normal university, hangzhou, china; bzhejiang Provincial Key laboratory of anti-cancer chinese medicines and natural medicines, hangzhou normal university, hangzhou, china; ccollege of life and Environmental sciences, hangzhou normal university, hangzhou, china; dschool of clinical medicine, hangzhou normal university, hangzhou, china; eclinical research Institute, zhejiang Provincial People’s hospital (affiliated People’s hospital), hangzhou medical college, hangzhou, P. r. china  \nABSTRACT  \nPaRP1 inhibitors are FDa-approved for BRca1/2-mutated breast cancer but show limited efficacy in wild-type cancers and face resistance issues. to overcome these, we designed novel 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based compounds integrating PaRP1 inhibitor pharmacophores with the atR inhibitor aZD6738 scaffold. substituent modifications influenced PaRP1 and atR selectivity, yielding dual inhibitors or selective PaRP1 inhibitors. compound 38a, the lead candidate, exhibited potent dual inhibition (ic50 \u003C 20 nM) and strong antitumor effects in MDa-MB-231 (ic50 \u003C 0.048 μM) and MDa-MB-468 (ic50: 0.01 μM) cell lines in vitro. Mechanistically, 38a arrested cell cycle progression, induced apoptosis, inhibited colony formation and migration, and suppressed DNa damage repair pathways, outperforming combined Niraparib andaZD6738. these findings underscore the therapeutic potential of PaRP1/atR dual inhibitors for breast cancer and support further investigation.  \nIntroduction  \nARTICLE HISTORY  \nReceived 26 November 2025  \nRevised 15 January 2026 accepted 1 February 2026  \nKEYWORDS  \nPaRP1; atR; dual inhibitors; breast cancer; anticancer  \nBreast cancer remains a leading cause of mortality among women worldwide, despite significant advancements in therapeutic strategies.1,2 suboptimal treatment outcomes and acquired drug resistance contribute to limiting therapeutic strategy applications and clinical success, underscoring the urgent need for novel therapeutic targets and approaches. PaRP1 plays an important role in DNa damage repair (DDR) . mechanistically, PaRP1 facilitates single-strand break (ssB) repair via the base excision repair (BeR) pathway by catalysing protein aDP-ribosylation.3 PaRP1 inhibitors (PaRPi) exploit this role to induce synthetic lethality in BRca1/2-mutated tumours, where homologous recombination repair (hRR) is compromised.3–6 clinically approved PaRPi, such as Olaparib ( 1), Rucaparib (2), Niraparib (3), talazoparib (4), Fluzoparib (5), Pamiparib (6), and Veliparib (7) (Figure 1(a)), have transformed treatment for BRca1/2-mutated breast and ovarian cancers.7,8 however, resistance to PaRPi monotherapy, driven by mechanisms such as h RR restoration, replication fork stabilisation, or alternative DDR activation, limits their efficacy, particularly in triple-negative breast cancer (tNBc) with BRca wild-type.9–11  \nto address these limitations, dual-target inhibition strategies have emerged to enhance synthetic lethality and overcome resistance. a promising approach involves co-targeting PaRP1 and atR kinase, a  \nCONTACT Xiang-yang ye  [xyye@hznu.edu.cn](xyye@hznu.edu.cn)  school of Pharmacy, hangzhou normal university, hangzhou, zhejiang311121, Pr china; zhejiang Provincial Key laboratory of anti-cancer chinese medicines and natural medicines, hangzhou normal university, hangzhou, zhejiang311121, P.r. china; yuan Gao  [gaoyuan@hmc.edu.cn](gaoyuan@hmc.edu.cn)  clinical research Institute, zhejiang Provincial People’s hospit","cbCaibw3b3bdeu5S","https://ap.wps.com/l/cbCaibw3b3bdeu5S","pdf",4023709,35,"English","# Abstract\n## Introduction\n## Article history\n## Keywords","[{\"question\":\"Why were new PARP1/ATR dual inhibitors designed for breast cancer?\",\"answer\":\"PARP1 inhibitors are effective mainly for BRCA1/2-mutated tumors, but resistance and limited efficacy occur in wild-type cancers. Co-targeting PARP1 and ATR is intended to overcome resistance linked to DNA damage repair and replication stress responses.\"},{\"question\":\"How was the compound series constructed in the study?\",\"answer\":\"The researchers designed 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based compounds by integrating PARP1 inhibitor pharmacophores with the ATR inhibitor AZD6738 scaffold. Substituent modifications were used to tune PARP1 and ATR selectivity.\"},{\"question\":\"What key in vitro effects did the lead compound 38a show?\",\"answer\":\"Compound 38a produced potent dual inhibition and strong anti-tumor activity in MDA-MB-231 and MDA-MB-468 cells. Mechanistically, it arrested the cell cycle, induced apoptosis, inhibited colony formation and migration, and suppressed DNA damage repair pathways.\"}]","Design, synthesis and anti-breast cancer activity evaluation of 6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidine-based PARP1/ATR dual inhibitors | PDF",1790115993,88,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/56cb23dd50e3b9b77735705ab0619bc0.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f4cf19ab05a81b30642a57670ea8f3e.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/10988264f7fdb2b7a35b4542b3dd7865.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f38fd9f38c7c97906561c0075a948197.webp",980,1306]